Phase 1 N=13 A Study in Healthy Smokers to Investigate the Effect of Food on the Bioavailability of Cytisine in a New Formulation
Smoking Cessation
Primary: Maximum Concentration (Cmax) — 26.2; 32.9 ng/mL
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=13 Phase Ib Study of SUnitinib Alternating With REgorafenib in Patients With Metastatic and/or Unresectable GIST
Gastrointestinal Stromal Tumor
Primary: Number of Participants With Serious and Non-Serious Adverse Events — 4; 5; 4 Participants
Phase 1 N=24 Muscadine Grape Skin Extract in Treating Patients With Malignancy That Is Metastatic or Cannot Be Removed by Surgery
Advanced Malignant Neoplasm · Metastatic Malignant Neoplasm · Unresectable Malignant Neoplasm
Primary: Number of Participants With Dose-Limiting Toxicity — 0; 1; 0; 0 Participants
Phase 1 N=24 Bioequivalence Study Between Levocetirizine Oral Disintegrating Tablet (ODT) and Levocetirizine Immediate Release Tablet (IRT)
Rhinitis
Primary: Part 1: Area Under the Concentration-time Curve (AUC) From Time Zero Time (Pre-dose) to the Time of Last Quantifiable Concentration (AUC[0-t]) of Levocetirizine…
Phase 1 N=19 A Study of LY2940680 in Japanese Participants With Advanced Cancers
Neoplasm Metastasis
Primary: Number of Participants With LY2940680 Dose-Limiting Toxicities (DLT) — 0; 0; 3 Participants
Phase 1 N=40 A Study to Evaluate Safety, Tolerability and Pharmacokinetics of Ascending Oral Single Dose of TAK-418 in Healthy Participants
Healthy Participants
Primary: Number of Participants Reporting One or More Treatment-emergent Adverse Events (TEAEs) — 4; 2; 2; 3 participants
Phase 1 N=53 Storytelling Narrative Communication Intervention for Smoking Cessation in Women Living With HIV
HIV/AIDS
Primary: Adherence Rate — 20; 17 Participants — p=0.29
Phase 1 N=23 A Phase 1 Study of IXAZOMIB in Adult Patients With Advanced Nonhematologic Malignancies
Advanced Non-hematologic Malignancies
Primary: Part 1: Number of Participants With Dose Limiting Toxicity (DLT) — 0; 0; 0; 1 participants
Phase 1 N=135 Injection of Local Anesthetic to Trocar Insertion Sites After Laparoscopy
Pain, Postoperative
Primary: Postoperative Pain Score Evaluated by Numerical Rating Scale (NRS) — 4.1; 3.4 units on a scale
Phase 1 N=15 First-in-Human Study of the Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic Profile of VX-984 in Combination With Chemotherapy
Advanced Solid Tumor
Primary: Part A: Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious TEAEs — 3; 3; 6; 3 Participants
Phase 1 N=24 Safety Study of Intratumoral Injection of Clostridium Novyi-NT Spores to Treat Patients With Solid Tumors That Have Not Responded to Standard Therapies
Solid Tumor Malignancies
Primary: Number of Patients With Treatment-emergent Adverse Events (TEAE) — 3; 3; 4; 6 Patients
Phase 1 N=74 Study to Evaluate Safety, Tolerability and Pharmacokinetics of rhNGF Eye Drops in Healthy Volunteers
Healthy
Primary: Changes in VAS Ocular Tolerability — -1; 0; 0; 3 units on a scale
Phase 1 N=17 Alisertib and Fractionated Stereotactic Radiosurgery in Treating Patients With Recurrent High Grade Gliomas
Adult Anaplastic Astrocytoma · Adult Anaplastic Ependymoma · Adult Anaplastic Oligodendroglioma
Primary: Maximum Tolerated Dose (MTD) of Alisertib — 50 mg dose of Alisertib
Phase 1 N=24 Bioavailability Study of COQUN ORAL FORMULATION
Male & Female Healthy Volunteers
Primary: Analysis of Pharmacokinetic Property "Area Under the Curve" — 2657.45; 3459.05 microg/l*days
Phase 1 N=29 Sulforaphane as an Antagonist to Human PXR-mediated Drug-drug Interactions
Adverse Drug Interactions
Primary: Midazolam Clearance (Pharmacokinetic Measure of Cytochrome P450 3A4 Activity) — 604; 552; 541; 156 ng*min/ml